HEART & LUNG is a premier academic journal published by MOSBY-ELSEVIER, focusing on the critical intersections of cardiology, critical care, and respiratory medicine. Since its inception in 1973, the journal has established a significant reputation within the medical community, as evidenced by its impressive Q2 ranking in key categories such as Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, and Pulmonary and Respiratory Medicine for the year 2023. With a dedicated readership comprising researchers, healthcare professionals, and students, HEART & LUNG serves as a vital platform for disseminating cutting-edge research, clinical innovations, and comprehensive reviews that influence practice standards and enhance patient care. While it currently does not offer Open Access options, readers can access a wealth of information pivotal to the advancement of medical knowledge and practice through conventional subscription. Explore the latest findings and contribute to the ever-evolving landscape of cardiovascular and respiratory health through this esteemed journal.

Annals of Thoracic Medicine is a prominent open-access journal, published by Wolters Kluwer Medknow Publications, focusing on the critical fields of cardiology, pulmonary and respiratory medicine, and surgery. With an ISSN of 1817-1737 and an E-ISSN of 1998-3557, this journal aims to disseminate cutting-edge research, clinical findings, and innovative practices that can significantly impact the health outcomes of patients dealing with thoracic diseases. Since its inception in 2006, it has established itself as a reputable source of knowledge, achieving Q2 quartile rankings in 2023 across its main categories. Currently ranked #126 in Medicine & Surgery and exhibiting a growing SCOPUS percentile, the journal plays an essential role in advancing the understanding and treatment of thoracic conditions. Open access options ensure that research is readily available to a global audience, facilitating collaboration and knowledge sharing among researchers, healthcare professionals, and students in the field.

Lung India is a premier open-access journal dedicated to the dissemination of high-quality research in the field of Pulmonary and Respiratory Medicine. Published by Wolters Kluwer Medknow Publications, it has been forging a path in respiratory healthcare since its inception in 2004. With its impactful contributions to clinical practice and research, Lung India holds a solid position in the academic landscape, evidenced by its ranking in the Q3 quartile for Pulmonary and Respiratory Medicine as of 2023, and its Scopus rank of #99 out of 155. The journal is particularly important for researchers, clinicians, and students in India and beyond, providing a platform for the latest findings and developments in respiratory care, lung disease management, and innovative treatment methods. With a commitment to accessibility, Lung India aims to promote knowledge sharing among professionals and support the advancement of respiratory health. The journal is well-equipped to cater to a diverse audience, ensuring that vital research is readily accessible and impactful.

Zeitschrift für Pneumologie is a pivotal journal in the field of Pulmonary and Respiratory Medicine, published by Springer Heidelberg, a renowned name in academic publishing. With its ISSN number 2731-7404, it serves as a vital platform for disseminating innovative research and clinical studies relevant to lung health and diseases. This German-based journal aims to bridge the gap between research and practice, encouraging submissions that advance knowledge in respiratory medicine, including pathophysiology, treatment modalities, and patient care strategies. Although currently categorized in the Q4 quartile within its field, its commitment to quality research and emerging insights positions it as an essential resource for researchers, healthcare professionals, and students dedicated to improving respiratory health. The journal operates within the convergence period from 2022 to 2024, promising a dynamic evolution of its content. With limited open access availability, it encourages readership and contribution from its audience, fostering a collaborative academic environment.

Welcome to Pulmonary Pharmacology & Therapeutics, a leading journal dedicated to the dissemination of innovative research and insights in the fields of pulmonary medicine and pharmacology. Published by Academic Press Ltd - Elsevier Science Ltd, this journal has made significant contributions to the academic community since its inception in 1997, with an ongoing commitment to relevant advancements projected through to 2024. With reputable Q2 rankings across vital categories including Biochemistry (medical), Medicine (miscellaneous), Pharmacology (medical), and Pulmonary and Respiratory Medicine, Pulmonary Pharmacology & Therapeutics is ranked in the top tier of its field, reflecting its impact on the discipline as evidenced by its Scopus rankings. Researchers, healthcare professionals, and students alike can access a wealth of high-quality articles that address the complexity of pulmonary diseases and therapeutic strategies, supporting research and clinical practice alike. Join the vibrant community contributing to this essential field and explore the latest findings that can drive change in patient care and therapeutic effectiveness.

RESPIROLOGY is a prestigious academic journal that focuses on the field of Pulmonary and Respiratory Medicine, publishing high-quality research and comprehensive reviews that contribute significantly to the understanding and management of respiratory health. As a distinguished publication of WILEY, it has established a strong presence in the academic world with an impressive impact factor and ranked in the Q1 category, recognized for its influence and innovation in the field. RESPIROLOGY is committed to disseminating cutting-edge research from 1996 through 2024, appearing regularly in SCOPUS with a rank of #14 out of 155, placing it in the rarefied 91st percentile among its peers. The journal invites contributions from researchers, professionals, and students, fostering a collaborative space for advancing knowledge in pulmonary medicine. Although it does not offer open access, its readership spans globally, indicating the high regard in which it is held within the scientific community.

The AMERICAN JOURNAL OF RESPIRATORY CELL AND MOLECULAR BIOLOGY, published by the esteemed American Thoracic Society, is a premier platform dedicated to advancing knowledge in the fields of pulmonary and respiratory medicine, cell biology, and clinical biochemistry. With an impressive impact factor and recognition as a Q1 journal in multiple categories for 2023, it ranks among the top tier of scholarly publications, evidencing its influence and contribution to the scientific community. Since its inception in 1989, the journal has provided a critical forum for researchers and professionals to disseminate innovative findings and pivotal reviews, driving forward the frontiers of respiratory biology. While the journal currently operates under traditional access mechanisms, it seeks to bridge gaps in research by presenting high-quality articles that address vital health challenges. As a key resource for both established researchers and emerging scholars in molecular biology and respiratory science, this journal plays a pivotal role in shaping the future of respiratory health advancements.

Annals of the American Thoracic Society is a premier journal dedicated to advancing the field of pulmonary and respiratory medicine. Published by the American Thoracic Society, this journal offers an invaluable platform for researchers and clinicians to disseminate cutting-edge research, clinical insights, and innovative methodologies. With an impressive impact factor and ranked in the top Q1 category of its field (2023) and within the top 20 of 155 according to Scopus rankings, it is positioned as a leading force in shaping clinical practice and research directions. The journal's convergence years from 2013 to 2024 indicate a commitment to providing timely and relevant content at the forefront of pulmonary health. While not an open-access journal, it ensures broad accessibility to its significant contributions in respiratory medicine, making it an essential resource for professionals, researchers, and students alike endeavoring to deepen their understanding and improve outcomes in thoracic health.

American Journal of Respiratory and Critical Care Medicine, published by the American Thoracic Society, is a leading scholarly journal dedicated to advancing the fields of critical care and pulmonary medicine. With an impressive impact factor and recognized in the Q1 quartile for both Critical Care and Pulmonary Medicine, this journal is essential reading for researchers, clinicians, and students invested in innovative practices and therapies in respiratory health. Through high-quality, peer-reviewed research articles, the journal addresses significant contemporary issues in respiratory and critical care, offering unparalleled insights and fostering interdisciplinary collaboration. Although the journal adheres to a traditional subscription model, it remains a cornerstone for those wishing to stay at the forefront of medical science in this vital area. With its extensive historical context since its establishment in 1991 and continuous publication spanning through 2024, the journal is committed to promoting discourse and disseminating knowledge that ultimately enhances patient care and clinical outcomes.

Pulmonary Circulation is a leading open-access journal published by Wiley, focused on advancing the field of pulmonary and respiratory medicine. Established in 2011, the journal has garnered a prestigious reputation, achieving a Q2 ranking in 2023 among its category and ranking #70 out of 155 in Scopus within the specialty of Medicine – Pulmonary and Respiratory Medicine, reflecting its growing influence and relevance in the scientific community. With its commitment to delivering high-quality, peer-reviewed research, Pulmonary Circulation serves as a vital resource for researchers, clinicians, and students seeking to explore innovative ideas and findings in lung health, pulmonary vascular diseases, and therapeutic approaches. The journal has been open access since 2017, ensuring that groundbreaking research is accessible to a wider audience, thus promoting collaboration and knowledge exchange in this dynamic field. Located in the heart of the United States at 111 River St, Hoboken, NJ 07030-5774, the journal is dedicated to fostering advancements in pulmonary health and addressing real-world challenges facing patients globally.